About: Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19
Creator	Lu, Hongzhou Xu, Qingnian Liu, Li Huang, Wei Chen, Jun Xia, Lu Huang, Dan Ling, Yun Xu, Shuibao Shen, Yingzhong Song, Shuli
Source	Medline; PMC
abstract	BACKGROUND: We aimed to evaluate the antiviral activity and safety of Darunavir/Cobicistat (DRV/c) in treating COVID-19 patients. METHODS: In this single-center, randomized and open-label trial, mild patients with PCR confirmed COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top of interferon alpha 2b inhaling or interferon alpha 2b inhaling alone. The primary endpoint was the virological clearance rate of oropharyngeal swabs at day 7 after randomization in the intention-to-treat population. (clinicaltrials.gov: NCT04252274) RESULTS: From Jan 30, 2020 to Feb 6, 2020, a total of 30 patients were enrolled, of whom 18(60%) were male, aged 47·2±2·8 years. 63·3% (19/30) of the participants had fever and 46·7%(14/30) had cough at enrollment. The participants were randomized at 4(2-5) days after onset of symptoms. The proportions of negative PCR results at day 7 was 46·7%(7/15) and 60·0%(9/15) in the DRV/c and the control group (P=0·72), respectively. The viral clearance rate at day 3 was both 20%(3/15) in the two study groups while the number increased to 26·7%(4/15) in the DRV/c group and maintained 20%(3/15) in the control group at day 5. Fourteen days after randomization, 1 participant in the DRV/c group progressed to critical illness and discontinued DRV/c while all the patients in the control group were stable (P=1·0). The frequency of adverse events in the two groups were comparable. CONCLUSION: Five days of DRV/c did not increase the proportion of negative conversion than standard of care alone, although it was well tolerated.
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.1093/ofid/ofaa241
bibo:pmid	32671131
has license	cc-by-nc-nd
sha1sum (hex)	b0f1dc41a803b77a3240f5bcc6472c76b3dcb785
schema:url	https://doi.org/10.1093/ofid/ofaa241
resource representing a document's title	Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19
has PubMed Central identifier	PMC7337805
has PubMed identifier	32671131
schema:publication	Open Forum Infect Dis
resource representing a document's body	covid:b0f1dc41a803b77a3240f5bcc6472c76b3dcb785#body_text
is schema:about of	covid:arg/b0f1dc41a803b77a3240f5bcc6472c76b3dcb785 named entity 'safety' named entity 'COVID-19' named entity 'Darunavir/Cobicistat' named entity 'DRV' named entity 'clinical characteristics' named entity 'dyslipidemia' named entity 'White blood cells' named entity 'randomized controlled study' named entity 'oropharyngeal' named entity 'pneumonia' named entity 'STATA' named entity '95% CI' named entity 'hazard ratio' named entity 'clearance rate' named entity 'standard of care' named entity 'coronavirus disease' named entity 'RT-PCR' named entity 'DRV' named entity 'phase III' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'adverse events' named entity 'DRV' named entity 'oral administration' named entity 'anemia' named entity 'respiratory failure' named entity 'viral shedding' named entity 'DRV' named entity 'Renal dysfunction' named entity 'COVID' named entity 'MERS-CoV' named entity 'Chinese Center for Disease Prevention and Control' named entity 'protease' named entity 'case-control studies' named entity 'transaminase' named entity 'LPV' named entity 'COVID-19' named entity 'kidney dysfunction' named entity 'standard of care' named entity 'antiviral' named entity 'informed consent' named entity 'bilateral pneumonia' named entity 'DRV' named entity 'LPV' named entity 'reverse transcriptase polymerase chain reaction' named entity 'kidney diseases' named entity 'partial pressure' named entity 'DRV' named entity 'adverse events' named entity 'confidence intervals' named entity 'drug-related' named entity 'CDC' named entity 'antiviral' named entity 'SARS-COV-2' named entity 'control group' named entity 'sample size' named entity 'control group' named entity 'DRV' named entity 'lopinavir/ritonavir' named entity 'clearance rate' named entity 'antiviral activity' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'adverse events' named entity 'infection' named entity 'HIV-1 protease' named entity 'SARS' named entity 'mortality rate' named entity 'cytochrome P450'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software